These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37069326)

  • 1. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
    Réa D; Boquimpani C; Mauro MJ; Minami Y; Allepuz A; Maheshwari VK; D'Alessio D; Wu Y; Lawrance R; Narbutas S; Sharf G; Hochhaus A
    Leukemia; 2023 May; 37(5):1060-1067. PubMed ID: 37069326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
    Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
    Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
    Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
    Int J Hematol; 2024 Sep; 120(3):305-313. PubMed ID: 38888812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
    Hochhaus A; Réa D; Boquimpani C; Minami Y; Cortes JE; Hughes TP; Apperley JF; Lomaia E; Voloshin S; Turkina A; Kim DW; Abdo A; Fogliatto LM; le Coutre P; Sasaki K; Kim DDH; Saussele S; Annunziata M; Chaudhri N; Chee L; García-Gutiérrez V; Kapoor S; Allepuz A; Quenet S; Bédoucha V; Mauro MJ
    Leukemia; 2023 Mar; 37(3):617-626. PubMed ID: 36717654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.
    Cortes JE; Rea D; Mauro MJ; Tran D; Wang P; Jadhav K; Yocolly A; Sasaki K
    J Med Econ; 2023; 26(1):915-923. PubMed ID: 37431294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
    Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
    Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
    Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
    Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Crescenzo R; Mamolo C; Reisman A; Hochhaus A; Brümmendorf TH;
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1589-1599. PubMed ID: 30989330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
    Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
    Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
    Monestime S; Al Sagheer T; Tadros M
    Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
    Combes FP; Li YF; Hoch M; Lorenzo S; Ho YY; Sy SKB
    Clin Pharmacol Ther; 2022 Nov; 112(5):1040-1050. PubMed ID: 35776072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP.
    Atallah EL; Wei D; Latremouille-Viau D; Rossi C; Damon A; Ferreira G; Guérin A; Jadhav K
    Clin Lymphoma Myeloma Leuk; 2024 Sep; ():. PubMed ID: 39426944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
    Trask PC; Cella D; Besson N; Kelly V; Masszi T; Kim DW
    Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
    Brümmendorf TH; Gambacorti-Passerini C; Bushmakin AG; Cappelleri JC; Viqueira A; Reisman A; Isfort S; Mamolo C
    Ann Hematol; 2020 Jun; 99(6):1241-1249. PubMed ID: 32307568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
    Schoenbeck KL; Flynn KE
    Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
    Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
    Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
    Ono T; Hino M; Matsumura I; Fujisawa S; Ishizawa K; Sakaida E; Sekiguchi N; Ono C; Aizawa M; Tanetsugu Y; Koide Y; Takahashi N
    Int J Hematol; 2022 Dec; 116(6):871-882. PubMed ID: 35963986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.